296 related articles for article (PubMed ID: 18178863)
41. Cathepsin K Deficiency Ameliorates Systemic Lupus Erythematosus-like Manifestations in
Zhou Y; Chen H; Liu L; Yu X; Sukhova GK; Yang M; Kyttaris VC; Stillman IE; Gelb B; Libby P; Tsokos GC; Shi GP
J Immunol; 2017 Mar; 198(5):1846-1854. PubMed ID: 28093526
[TBL] [Abstract][Full Text] [Related]
42. Alleviation of renal disease and lymphadenopathy in MRL-Fasp(lrcg)/Fas(lprcg) (MR-lpr(cg)) mice neonatally infected with mouse mammary tumor virus encoding superantigen strongly reactive with TCR Vbeta8.2 element.
Matsuzawa A; Yasuda T; Zhang Y; Nagase H; Yoshimoto T; Kimura M; Tsubura A
Viral Immunol; 2000; 13(3):297-311. PubMed ID: 11016595
[TBL] [Abstract][Full Text] [Related]
43. Nephritogenicity of the lprcg gene on the MRL background.
Kimura M; Ogata Y; Shimada K; Wakabayashi T; Onoda H; Katagiri T; Matsuzawa A
Immunology; 1992 Jul; 76(3):498-504. PubMed ID: 1526655
[TBL] [Abstract][Full Text] [Related]
44. IFN-gamma is essential for the development of autoimmune glomerulonephritis in MRL/Ipr mice.
Haas C; Ryffel B; Le Hir M
J Immunol; 1997 Jun; 158(11):5484-91. PubMed ID: 9164971
[TBL] [Abstract][Full Text] [Related]
45. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection.
Atkinson C; Song H; Lu B; Qiao F; Burns TA; Holers VM; Tsokos GC; Tomlinson S
J Clin Invest; 2005 Sep; 115(9):2444-53. PubMed ID: 16127466
[TBL] [Abstract][Full Text] [Related]
46. Analysis of C4 and the C4 binding protein in the MRL/lpr mouse.
Wenderfer SE; Soimo K; Wetsel RA; Braun MC
Arthritis Res Ther; 2007; 9(5):R114. PubMed ID: 17971229
[TBL] [Abstract][Full Text] [Related]
47. Retinoic acid treatment protects MRL/lpr lupus mice from the development of glomerular disease.
Pérez de Lema G; Lucio-Cazaña FJ; Molina A; Luckow B; Schmid H; de Wit C; Moreno-Manzano V; Banas B; Mampaso F; Schlöndorff D
Kidney Int; 2004 Sep; 66(3):1018-28. PubMed ID: 15327395
[TBL] [Abstract][Full Text] [Related]
48. Complement Properdin Determines Disease Activity in MRL/
Alaridhee H; Alharbi A; Saeed Z; Thomas RC; Stover CM
Medicina (Kaunas); 2020 Aug; 56(9):. PubMed ID: 32867176
[No Abstract] [Full Text] [Related]
49. Administration of the soluble complement inhibitor, Crry-Ig, reduces inflammation and aquaporin 4 expression in lupus cerebritis.
Alexander JJ; Bao L; Jacob A; Kraus DM; Holers VM; Quigg RJ
Biochim Biophys Acta; 2003 Nov; 1639(3):169-76. PubMed ID: 14636948
[TBL] [Abstract][Full Text] [Related]
50. Absence of CD59 exacerbates systemic autoimmunity in MRL/lpr mice.
Miwa T; Zhou L; Maldonado MA; Madaio MP; Eisenberg RA; Song WC
J Immunol; 2012 Dec; 189(11):5434-41. PubMed ID: 23109726
[TBL] [Abstract][Full Text] [Related]
51. CTLA4IgG gene delivery prevents autoantibody production and lupus nephritis in MRL/lpr mice.
Takiguchi M; Murakami M; Nakagawa I; Saito I; Hashimoto A; Uede T
Life Sci; 2000; 66(11):991-1001. PubMed ID: 10724446
[TBL] [Abstract][Full Text] [Related]
52. Targeted mouse complement inhibitor CR2-Crry protects against the development of atherosclerosis in mice.
Liu F; Wu L; Wu G; Wang C; Zhang L; Tomlinson S; Qin X
Atherosclerosis; 2014 May; 234(1):237-43. PubMed ID: 24685815
[TBL] [Abstract][Full Text] [Related]
53. Targeting the Immune Complex-Bound Complement C3d Ligand as a Novel Therapy for Lupus.
Kulik L; Laskowski J; Renner B; Woolaver R; Zhang L; Lyubchenko T; You Z; Thurman JM; Holers VM
J Immunol; 2019 Dec; 203(12):3136-3147. PubMed ID: 31732528
[TBL] [Abstract][Full Text] [Related]
54. IFN-gamma receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Fas(lpr) mice.
Schwarting A; Wada T; Kinoshita K; Tesch G; Kelley VR
J Immunol; 1998 Jul; 161(1):494-503. PubMed ID: 9647261
[TBL] [Abstract][Full Text] [Related]
55. Use of genetic knockouts to modulate disease expression in a murine model of lupus, MRL/lpr mice.
Reilly CM; Gilkeson GS
Immunol Res; 2002; 25(2):143-53. PubMed ID: 11999168
[TBL] [Abstract][Full Text] [Related]
56. Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus.
Pawar RD; Ramanjaneyulu A; Kulkarni OP; Lech M; Segerer S; Anders HJ
J Am Soc Nephrol; 2007 Jun; 18(6):1721-31. PubMed ID: 17460144
[TBL] [Abstract][Full Text] [Related]
57. Treatment of MRL/lpr mice, a genetic autoimmune model, with the Ras inhibitor, farnesylthiosalicylate (FTS).
Katzav A; Kloog Y; Korczyn AD; Niv H; Karussis DM; Wang N; Rabinowitz R; Blank M; Shoenfeld Y; Chapman J
Clin Exp Immunol; 2001 Dec; 126(3):570-7. PubMed ID: 11737078
[TBL] [Abstract][Full Text] [Related]
58. Complement Inhibition Alleviates Cholestatic Liver Injury Through Mediating Macrophage Infiltration and Function in Mice.
Guo Z; Chen J; Zeng Y; Wang Z; Yao M; Tomlinson S; Chen B; Yuan G; He S
Front Immunol; 2021; 12():785287. PubMed ID: 35069557
[TBL] [Abstract][Full Text] [Related]
59. Pathogenesis of early nephritis in lupus prone mice with a genetic accelerating (lpr) factor.
Granholm NA; Cavallo T
Autoimmunity; 1994; 17(3):195-202. PubMed ID: 7948604
[TBL] [Abstract][Full Text] [Related]
60. Endogenous Tim-1 promotes severe systemic autoimmunity and renal disease MRL-Fas(lpr) mice.
Nozaki Y; Kitching AR; Akiba H; Yagita H; Kinoshita K; Funauchi M; Matsumura I
Am J Physiol Renal Physiol; 2014 May; 306(10):F1210-21. PubMed ID: 24623145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
